Kim Kamdar
About Kim Kamdar
Kim Kamdar Company Affiliations
Kim Kamdar is a Managing Partner at Domain Associates, a venture capital fund focused on the healthcare sector. She was the founding CEO for Truvian Sciences and currently serves as its Chair. Kamdar has played significant roles in multiple companies, including Ariosa Diagnostics until its acquisition by Roche, Corthera until its sale to Novartis, and BiPar Sciences until its sale to Sanofi. She is also an early investor and co-creator of companies such as Aspen Neuroscience, Syndax Pharmaceuticals, and Adastra.
Kim Kamdar Board Memberships
Kim Kamdar holds Board of Directors memberships at several prominent biosciences firms, including Alume Biosciences, EPIC Sciences, Evofem Biosciences, Obalon, Sera Prognostics, and Singular Genomics. Additionally, she serves on the Advisory Board for Dr. Eric Topol’s NIH-supported Clinical and Translational Science Award for Scripps Medicine and the Board of Directors for Access Youth Academy, a non-profit organization.
Kim Kamdar Background in Research and Venture Capital
Before her current role at Domain Associates, Kim Kamdar was a Kauffman Fellow at MPM Capital. She has extensive experience in research, having served as a Research Director at Novartis. At Novartis, Kamdar built and led a team focused on the biology, genetics, and genomics of model organisms. Her academic contributions include authoring ten papers and holding seven patents.
Kim Kamdar Education and Expertise
Kim Kamdar's educational background is grounded in biochemistry and genetics. She earned a B.A. from Northwestern University and a Ph.D. in biochemistry and genetics from Emory University. Her technical expertise is further showcased through her publication of ten research papers and her role as an inventor on seven patents.